Abrégé

The present invention describes a process for capturing CO2 using an optimized mixture of water and alcohols with alkali hydroxides, such as KOH and NaOH, for absorption of CO2 from gaseous mixtures. The process shows high efficiency and low volatility and corrosivity rate of the solvent, in addition to allowing cost reduction for installation and maintenance of reactors and reducing solvent loss. The present invention also describes a process for regenerating solvent or its reuse, carried out by chemical precipitation, continuously and not in batch, through the reaction with alkaline earth oxides, such as CaO and MgO, and/or alkaline earth hydroxides, such as Ca(OH)2 and Mg(OH)2, for the formation of carbonates, such as CaCO3 and MgCO3, which can be discarded in nature without any environmental issue or can be used commercially in industry or agriculture.

Classes IPC  ?

• B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
• B01D 53/62 - Oxydes de carbone
• B01D 53/78 - Procédés en phase liquide avec un contact gaz-liquide
• B01D 53/96 - Régénération, réactivation ou recyclage des réactifs

Abrégé

The present invention refers to the use of synthetic peptides built from the selection of peptides available on the surface of filamentous phages and that bind to the FabC4 antibody fragment with clinical relevance in the diagnosis of Breast Cancer (BC) and in the prognosis of Triple-Negative Breast Cancer (TNBC). The peptides were specific to tumor proteins and could be potentially used in immunodiagnostic tests, formulations coupled to fluorescent or radioactive particles for diagnostic imaging, therapeutic drug carriers, and in immunogenic compositions for BC management. The technology used for peptide selection was the peptide expression system on the surface of filamentous bacteriophage. The strategy used was the selection of binding peptides of tumor proteins present in serum from TNBC patients.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61P 35/00 - Agents anticancéreux
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention relates to the process of producing artificial aggregate from tailings from ore dams. The iron ore sandy tailings are mixed with a binder and, through the mixing and pelletizing process, form the artificial aggregate. The artificial aggregate produced has a spheroidal shape, a large size, a rough surface and a color that ranges between pink and dark red. This artificial aggregate is able to replace the natural aggregate, and can be used in the manufacture of a more resistant concrete, for the base and sub-base of roads, as a decorative element for gardens and beds, in addition to being a form of storage of ore dam tailings in the form of pellets, adding value to these tailings and reducing the environmental mining impacts.

Classes IPC  ?

• C04B 18/12 - DéchetsRésidus provenant de carrières, mines, ou analogues
• C04B 18/02 - Matières agglomérées
• C04B 7/12 - Pouzzolanes naturelsCiments de pouzzolanes naturels
• C04B 7/52 - Broyage fin
• C04B 14/06 - QuartzSable

Abrégé

The invention refers to the process of obtaining porous spheres based on CaO modified with carbon nanotubes for the capture of CO2. The invention also refers to the spheres obtained and their use to capture CO2 generated by a vehicular internal combustion engine, aiming to reduce the amount of CO2 released into the atmosphere.

Classes IPC  ?

• B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
• B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
• B01D 53/62 - Oxydes de carbone
• B01D 53/82 - Procédés en phase solide avec des réactifs à l'état stationnaire
• B01D 53/92 - Épuration chimique ou biologique des gaz résiduaires des gaz d'échappement des moteurs à combustion

Abrégé

The present invention describes the process of preparing ceramic materials for absorption of acidic gases, mainly carbon dioxide, in exhaust systems and/or present indoors. Ceramic materials are formed by a mixture of alkali carbonate with alkaline earth metal oxide/hydroxide associated with a binding component, but non-limiting. The alkali carbonate comprises sodium, potassium carbonate, or a mixture of both. The alkaline earth metal oxide/hydroxide may be formed from magnesium oxide or magnesium hydroxide as well as calcium oxide and/or calcium hydroxide.

Classes IPC  ?

• B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
• B01D 53/62 - Oxydes de carbone
• B01D 53/82 - Procédés en phase solide avec des réactifs à l'état stationnaire
• B01D 53/83 - Procédés en phase solide avec des réactifs en mouvement
• B01J 20/02 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique
• B01J 20/16 - Alumino-silicates
• B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
• B01J 20/30 - Procédés de préparation, de régénération ou de réactivation

Abrégé

The present invention describes a process for producing nanostructured material, produced from polymer waste doped with alkaline metals and/or alkaline earth metals, which is capable of capturing and storing CO2. The process for obtaining the material uses waste generated by the polymer industry and is therefore environmentally sustainable. The product produced, that is, the nanostructured material, shows high CO2 absorption capacity, being able to absorb up to 80% by weight in mass in CO2. In addition, the product produced shows low density, an important characteristic for application in vehicles. Therefore, the product obtained can be used for capturing and storing CO2 emitted by different emission sources, mainly mobile sources such as vehicles, but can also be used in industries such as the mining industry, oil industry, inter alia, in addition to the automotive industry.

Classes IPC  ?

• B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
• B01J 20/32 - Imprégnation ou revêtement
• B01J 20/26 - Composés macromoléculaires synthétiques
• B01D 53/14 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par absorption
• B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation

Abrégé

The present invention relates to a process for producing an artificial aggregate from ore mining dam waste. The iron ore sandy tailings are mixed with a binder and, by means of a process of mixing and pelleting, form the artificial aggregate. The artificial aggregate thereby produced has a spheroidal shape, is coarse, has a rough surface and a colour ranging from pink to dark red. Said artificial aggregate can be used as a replacement for a natural aggregate, and can be used for manufacturing stronger concrete, for the base and subbase of roads, as a decorative element for gardens and flower beds, and is also a means for storing ore mining dam waste in the form of pellets, adding value to said waste and reducing the impact of mining on the environment.

Classes IPC  ?

• C04B 18/30 - Déchets mélangésDéchets de composition indéterminée, p. ex. ordures ménagères
• C04B 18/12 - DéchetsRésidus provenant de carrières, mines, ou analogues
• C04B 7/22 - Ciments de minerais de fer

Abrégé

The present invention relates to the use of synthetic peptides constructed by selecting peptides displayed on the surface of filamentous phages that bind to the antibody fragment FabC4, which is of clinical relevance for the diagnosis of breast cancer (BC) and prognosis of triple-negative breast cancer (TNBC). The peptides were specific for tumour proteins and can potentially be used in immunodiagnostic tests, in formulations coupled to fluorescent or radioactive particles for diagnostic imaging, as therapeutic drug carriers and in immunogenic compositions for the management of BC. The technology used for selecting the peptides was the system of expression of peptides on the surface of filamentous bacteriophages. The strategy used was the selection of peptides that bind to tumour proteins present in the serum of patients with TNBC.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• G01N 33/531 - Production de matériaux de tests immunochimiques
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention describes a process for preparing ceramic materials for the absorption of acid gases, mainly carbon dioxide, in exhaust systems and/or present in closed environments. The ceramic materials are formed of a mixture of an alkaline carbonate and an alkaline earth metal oxide/hydroxide in combination with an agglomerating, but non-limiting, component. The alkaline carbonate comprises sodium or potassium carbonate, or a mixture thereof. The alkaline earth metal oxide/hydroxide can be formed of magnesium oxide or magnesium hydroxide, or calcium oxide and/or calcium hydroxide.

Classes IPC  ?

• B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium

Abrégé

2222333, which can be disposed of in nature without any environmental problem, or can be commercially used in industry or agriculture.

Classes IPC  ?

• B01D 53/62 - Oxydes de carbone
• B01D 53/78 - Procédés en phase liquide avec un contact gaz-liquide
• B01D 53/96 - Régénération, réactivation ou recyclage des réactifs
• C01B 32/50 - Anhydride carbonique
• C01B 32/60 - Préparation des carbonates ou des bicarbonates en général

Abrégé

2222 released into the atmosphere.

Classes IPC  ?

• B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
• B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation

Abrégé

22222 emitted by various emission sources, mainly mobile sources such as vehicles, but can also be used in industries such as the mining industry, oil industry, inter alia, in addition to the automotive industry.

Classes IPC  ?

• B01J 20/04 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des composés des métaux alcalins, des métaux alcalino-terreux ou du magnésium
• B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone libreCompositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
• B01J 20/285 - Absorbants ou adsorbants poreux à base de polymères
• B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
• B01D 53/02 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse
• B01D 53/62 - Oxydes de carbone
• B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
• B82Y 40/00 - Fabrication ou traitement des nanostructures

Abrégé

Described is a device for determining gestational age and methods for determining gestational age at birth by measuring parameters associated with photobiological properties of the skin such as reflectance or reflectivity by measuring diffused or scattered portions of the light beam incident on the skin, as well as the erythema index, along with clinical parameters of the newborn such as gender, the use of phototherapy, birth weight and time spent in incubator. The ability to obtain a realistic estimate of the age of the conceptus quickly, non-invasively and at low cost makes it possible to provide care suited to the needs of the newborn, to assess the chances of survival and to affect the short- and long-term prognosis of the newborn. The correct determination of gestational age at birth also influences clinical follow-up protocols in infancy and vital statistics.

Classes IPC  ?

• A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The present technology relates to molecules that stimulate the immune system for use in treating drug abuse and addiction, and to the methods of synthesis thereof. Said molecules comprise a calixarene chemical structure, preferably calix[4]arene and/or calix[8]arene, coupled to a hapten that is analogous to cocaine, preferably GNE and/or GNC. An anti-drug vaccine is also described, specifically an anti-cocaine vaccine, using said molecules. The anti-drug vaccine can also be used for preventing foetal exposure to drugs in pregnant women who use drugs and do not wish, or cannot manage, to interrupt the use of said drugs during pregnancy.

Classes IPC  ?

• C07D 451/04 - Composés hétérocycliques contenant des systèmes cycliques aza-8 bicyclo [3.2.1] octane, aza-9 bicyclo [3.3.1] nonane ou oxa-3 aza-9 tricyclo [3.3.1.02,4] nonane, p. ex. alcaloïdes du tropane ou du granatane, scopolamineLeurs acétals cycliques contenant des systèmes cycliques aza-8 bicyclo [3.2.1] octane ou oxa-3 aza-9 tricyclo [3.3.1.02,4] nonane sans autre condensation, p. ex. tropaneLeurs acétals cycliques avec des hétéro-atomes liés directement en position 3 du système cyclique aza-8 bicyclo [3.2.1] octane ou en position 7 du système cyclique oxa-3 aza-9 tricyclo [3.3.1.02,4] nonane
• C07D 451/12 - Atomes d'oxygène acylés par des acides carboxyliques aromatiques ou hétéro-aromatiques, p. ex. cocaïne
• A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
• A61K 39/385 - Haptènes ou antigènes, liés à des supports
• A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance

Abrégé

nestedprimersprimersprimers (second nested PCR reaction ) for 40 viral types, which include non-oncogenic, indeterminate and oncogenic types.

Abrégé

The present patent application describes a device for determining gestational age, methods for determining gestational age at birth by measuring parameters associated with the photobiological properties of the skin and clinical parameters of newborns. The technology makes it possible to determine gestational age at birth using photobiological properties of the skin such as the reflectance or reflectivity by measuring the diffused or scattered portions of the light beam incident on the skin, as well as the erythema index, along with clinical parameters of the newborn such as sex, the use of phototherapy, birth weight and time spent in incubator. The technology provides many advantages, since the ability to obtain a realistic estimate of the age of the conceptus quickly, non-invasively and at low cost makes it possible to provide care suited to the needs of the newborn, to assess the chances of survival and to affect the short- and long-term prognosis of the newborn. In population terms, it facilitates recognition of prematurity, which is relevant to public health policy worldwide. The correct determination of gestational age at birth also influences clinical follow-up protocols in infancy and vital statistics.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• G01N 21/55 - Réflexion spéculaire

Abrégé

The present invention relates to the use of the synthetic PnTx-19 peptide for preparing analgesic medicinal drugs for the treatment of patients suffering from neuropathic pain, nociceptive pain (sensitisation of nociceptors by prostaglandin E2) and inflammatory pain. The synthetic PnTx-19 peptide is a very interesting pharmacological tool for use as an analgesic medicinal drug, since it triggers an antinociceptive response via cannabinoid and opioid and probably does not develop drug tolerance or dependence.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• A61P 25/04 - Analgésiques centraux, p. ex. opioïdes

Abrégé

The present invention relates to a process for producing nanoscale carbonate hydroxyapatites (CHA) with dimensions of 1-10 nm obtained for a CO32- composition range of 0-14%, which are similar in terms of crystallinity and composition to human bone tissue, and are intended for use in medicine and dentistry. The material produced has CO32- compositional variability and has the chemical and physical features of the bone into which it is to be implanted, thereby stimulating natural bone integration and regeneration processes. Said material retains the same nanostructural and degradation-related features in vivo, for the purpose of selective and improved use thereof in implants, grafts and fillers for bones in various parts of the body.

Classes IPC  ?

• A61K 6/033 - Composés du phosphore, p.ex. apatite
• A61B 17/58 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet pour ostéosynthèse, p. ex. plaques, vis ou matériels de fixation
• A61K 33/42 - PhosphoreSes composés
• C07F 9/02 - Composés du phosphore

Abrégé

The subject matter relates to a method for producing urea pearls combined with aldimine by addition of urea pearls to a solution of aldimine in an organic solvent. After mechanical stirring and complete homogenisation, the organic solvent is evaporated. The product obtained by this method comprises incorporated or encapsulated urea pearls, or aldimine-coated urea pearls. These urea pearls are used to inhibit urease enzymes present in the soil, preferably to enhance the growth and development of agricultural corps produced using urea-based fertilizers.

Classes IPC  ?

• C05G 3/08 - Mélanges d'un ou plusieurs engrais avec des produits n'ayant pas une activité spécifique d'engrais avec des agents contrôlant dans le sol la nitrification des composés d'ammonium ou de l'urée
• C05C 9/00 - Engrais contenant de l'urée ou ses composés

Abrégé

Pichia pastoris and expression thereof from a recombinant peptide, which consists in a continuous sequence and of a recombinant peptide, respectively, and the drug composition based of said recombinant polypeptide.

Classes IPC  ?

• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present invention describes a new compound, the method for synthetising same and the use of this compound, as well as a pharmaceutical composition containing said compound. Specifically, the present invention discloses a compound of formula (I), its synthesis method and compositions containing said compound. In addition, the present invention also describes the use of the compound to produce a composition for treating, by therapy or prophylaxis, neurodegenerative diseases and inflammation, and also to produce anticholinesterase compositions. The present invention further describes treatment methods involving the administration of said compound.

Classes IPC  ?

• C07D 401/00 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote
• C07D 413/00 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle
• C07D 221/00 - Composés hétérocycliques contenant des cycles à six chaînons ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle, non prévus par les groupes
• C07D 227/00 - Composés hétérocycliques contenant des cycles ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle, prévus dans plus d'un groupe principal
• A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The present technology relates to a new heterologous expression process for the kinesin repeat, using specific primers which make it possible to construct a recombinant antigen with 7.5 repeats of K39 associated with a degenerated repeat, the KDDR (Kinesin Degenerated Derived Repeat). Also described is the use of this antigen (K39-KDDR) to diagnose leishmaniasis and as a vaccine, and a diagnostic kit containing this antigen.

Classes IPC  ?

• C07K 14/44 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de protozoaires
• A61K 39/008 - Antigènes de Leishmania
• C12N 15/30 - Gènes codant pour des protéines protozoaires, p. ex. Plasmodium, Trypanosoma, Eiméria
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose

Abrégé

The present invention pertains to the fields of biotechnology and genetic engineering, in particular to the expression of recombinant peptides. Innoculation of bovines with these peptides produces an immune response capable of destroying the Rhipicephalus microplus ticks feeding on the innoculated bovines, decreasing the number and reproductive ability of this species of tick. This recombinant immunogen can be used as an effective vaccine against ticks. The technical subject matter consists in the design and construction of two synthetic genes with preferencial Pichia pastoris codons and the expression by the same of a recombinant peptide having a continuous sequence and of a recombinant peptide, respectively; also disclosed is the medicinal composition based on said recombinant polypeptide(s).

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 33/14 - Antiparasites externes, p. ex. antiscabieux

Abrégé

The present technology describes a kit and an immunodiagnostic method for detecting malaria caused by Plasmodium vivax, which uses a peptide (SEQ ID NO. 1) comprising Plasmodium vivax merozoite surface protein 1 (PvMSP-1) as the antigenic marker, or the polymerized form thereof. Said peptides have proven to be highly specific in the identification of serum from anaemic individuals infected with Plasmodium vivax.

Classes IPC  ?

• A61K 39/15 - Reoviridae, p. ex. virus de la diarrhée du veau
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present invention relates to the preparation of the recombinant antigen of the viral capsid of Porcine circovirus 2 (PCV-2) and modifications thereof, by expression in a prokaryotic system, purification in the monomer form, recovery of virus-like particles (VLPs) and their use in vaccine formulations, diagnostic kits and a system for quantifying in vaccine lots the PCV-2 antigen by means of a capture ELISA assay. The antigens and vaccine formulations can be used for immunizing animals in programs for combatting PCV-2-associated diseases in conventional swine breeding systems, and represent alternatives to the commercially available vaccines. The ELISA kit can be used for testing the quality of commercial and/or experimental vaccines against PCV-2.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C07K 14/01 - Virus à ADN
• C12N 15/34 - Protéines de virus à ADN
• A61P 31/20 - Antiviraux pour le traitement des virus ADN
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet

Abrégé

The present technology describes a perfusion chamber for tissue culture, the chamber being made of a material that can include different types of polymer that have good thermal and electrical properties and moderate strength, and that are easy to machine and capable of being autoclaved, which is an essential factor when the intention is to work with biological material. In terms of the physical aspect thereof, the chamber may have different formats, provided the conditions for culture of the tissue of interest are complied with. The perfusion chamber developed makes it possible to achieve three‑dimensional culture of cells seeded in a matrix that, when correctly adapted to the perfusion chamber, promotes the passage of the flow through this scaffold, guaranteeing that the medium is able to reach the majority of the cells, if not all the cells, thereby promoting cell viability and proliferation.

Classes IPC  ?

• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/0775 - Cellules souches mésenchymateusesCellules souches dérivées du tissu adipeux
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention describes a method and kit for quantifying material of bovine and bubaline origin in milk or meat products and other products of animal origin, using a group of specific primers and probe. In order to quantify DNA, the TaqMan real-time PCR system is used as the standard, but the method is also suitable for the SYBR Green PCR system. The present invention further describes a new method for standardising the total quantity of DNA present in a given sample, and plotting calibration curves according to the type of material under analysis.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to the process for preparing a pharmaceutical formulation based on green propolis with antimicrobial properties, which can treat various odontological diseases, such as mucositis and buccal peri-implantitis Said formulation comprises a colloidal dispersion of glycolic propolis extract, composed of a non-ionic surfactant and a thickening agent capable of reducing the hydrophobicity of the extract and the tendency thereof to form precipitates in an aqueous medium. The formulation can be used via buccal administration.

Classes IPC  ?

• A61K 35/64 - Insectes, p. ex. abeilles, guêpes ou puces
• A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
• A61K 31/045 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates
• A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol
• A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
• A61K 8/97 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base d’algues, de champignons, de lichens ou de plantesCosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés à base de leurs dérivés
• A61K 9/10 - DispersionsÉmulsions
• A61P 31/02 - Antiseptiques locaux
• A61P 31/04 - Agents antibactériens
• A61Q 11/00 - Préparations pour le nettoyage des dents, de la bouche ou des prothèses dentaires, p. ex. dentifricesBains de bouche

Abrégé

The present invention relates to a pharmaceutical composition for treating visceral leishmaniasis, characterized in that it comprises the association of conventional liposomes and prolonged-circulation liposomes with a leishmanicidal-drug delivery system. Said composition may be used in the preparation of a medicinal product for treating leishmaniasis and may be administered intramuscularly, subcutaneously, intraperitoneally or intravenously. The use of this system enables the drug efficiently to reach all sites infected by the parasite, the pegylated liposomes promoting more effective targeting of the leishmanicidal drugs on the bone marrow and spleen, whilst the conventional liposomes contribute to the targeting of the drug on the liver.

Classes IPC  ?

• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 31/29 - Composés de l'antimoine ou du bismuth
• A61K 31/047 - Composés hydroxylés, p. ex. alcoolsLeurs sels, p. ex. alcoolates ayant plusieurs groupes hydroxyle, p. ex. sorbitol

Abrégé

The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.

Classes IPC  ?

• A61K 9/10 - DispersionsÉmulsions
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/51 - Nanocapsules
• A61K 31/431 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes contenant d'autres systèmes hétérocycliques, p. ex. ticarcilline, azlocilline, oxacilline
• A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/43 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes
• A61K 31/545 - Composés contenant des systèmes cycliques thia-5 aza-1 bicyclo [4.2.0] octane, c.-à-d. composés contenant un système cyclique de formule , p. ex. céphalosporines, céfaclor, céphalexine

Abrégé

One of the greatest difficulties encountered in the treatment of Chagas disease by chemotherapy is the natural resistance of T. cruzi to the pharmaceuticals available, and also the fact that parasites that are resistant to a certain compound are also resistant to other compounds. The same occurs in the treatment of cancer, where resistance to chemotherapeutic agents is daily increasing. The aim of the present invention is to provide substances having pharmacological activity and effectiveness for use as a pharmaceutical product for humans and animals, and useful for treating diseases caused by naturally resistant parasites, in particular T. cruzi and other parasites, such as those belonging to Leishmania species, and also for the treatment of cancer. The activity of furan heliangolide sesquiterpenoid compounds has been clearly verified in vivo and in vitro, in particular that of licnofolide (1), the NC-LIC presenting the best results (P < 0.005) for the treatment of infection by T. cruzi of mice infected with all the strains studied, including animals infected with the Colombian strain, which is 100% resistant to BZ, both with regard to parasitemia (CL, Y and Colombian strains) and survival of the animals (CL, Y and Colombian strains). Free lactone (free LIC9) also showed partial results for both parameters (parasitemia and survival). This confirms the previously studied activity of this lactone in vitro (Oliveira et al., Phytotherapy Research, 10(4), 292-295, 1996) and constitutes the first evidence of the potential of this substance for the treatment in vivo of parasite samples with different resistance or sensitivity profiles to drugs conventionally used for the treatment of human Chagas disease (benznidazole and nifurtimox). It was also demonstrated that the best results were observed with a formulation contained in polymeric nanocapsules obtained from PCL polymers and also from polylactic acid covalently bonded to polyethyleneglycol, the so-called stealth nanocapsules, which were described for the first time by Mosqueira et alia (Mosqueira et alia, Journal of Drug Targeting, vol. 7, no. 1, pages 65-78, 1999).

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 31/365 - Lactones
• A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention proposes an innovation in the process of colouring stainless steels in a sulphochromic solution by a pulsed current, in that the chrome content in the colouring bath is drastically smaller so as to increase the sustainability of the process. In the newly proposed method, the low chrome concentration, of between 4 and 43 g/L of CrO3 in the colouring solution, results in even cleaner technology, providing a more favourable working environment, and also a substantial decrease in production costs. The coloured stainless steels produced using this new method are homogenously coloured and have good resistance to abrasion, being comparable to those obtained using commercial processes, via electrochemistry. Other process parameters must be adjusted in order to compensate for the reduced amount of chrome and ensure product quality. The coloured stainless steel produced by means of the present invention can be used in the building and architecture industries, for covering external and internal walls, ceilings and roofs, sanitary metals, urban furniture, road signs and works of art such as sculptures. This process consists of the following steps: (1) degreasing, (2) washing, (3) electrochemical pre-treatment, (4) washing, (5) colouring in a sulphochromic solution with low chrome content, at a temperature of 25°C to 75°C, applying a current, followed by (6) washing, (7) electrochemical hardening and (8) washing.

Classes IPC  ?

• C25D 5/18 - Dépôt au moyen de courant modulé, pulsé ou inversé

Abrégé

The invention relates to proteins of the family of recombinant E-NTPDases that can be used as antigens in diagnostic kits for various types of animal and human leishmaniasis. The thus obtained proteins of the family of the recombinant E-NTPDases can be used for producing diagnostic kits for detecting antibodies in various types of leishmaniasis, using immonological assays. These tests can be used for the detection of seropositive individuals in leishmaniasis screening programs or in laboratory tests for various types of leishmaniasis. These proteins can also be used in prognostic and immunisation assays, to rationalise the design of chemotherapeutic drugs for the treatment of various types of leishmaniasis and to develop monoclonal antibodies for use in the diagnostic, prognostic or therapy of various types of leishmaniasis.

Classes IPC  ?

• C12N 9/16 - Hydrolases (3.) agissant sur les liaisons esters (3.1)
• C12N 15/30 - Gènes codant pour des protéines protozoaires, p. ex. Plasmodium, Trypanosoma, Eiméria
• C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.

Classes IPC  ?

• A61K 9/51 - Nanocapsules
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 31/431 - Composés contenant des systèmes cycliques thia-4 aza-1 bicyclo [3.2.0] heptane, c.-à-d. composés contenant un système cyclique de formule , p. ex. pénicillines, pénèmes contenant d'autres systèmes hétérocycliques, p. ex. ticarcilline, azlocilline, oxacilline
• A61P 31/04 - Agents antibactériens

Abrégé

The present invention relates to a level sensor that can be implemented at a low cost, without affecting already existing interfaces, and that identifies the real volume of fuel in a vehicle tank, dampening oscillations and correcting level differences at the surface of the fuel caused by movements of the vehicle. The high-precision, oscillation-proof fuel level sensor according to the present invention comprises a central module (1) with an electric connection point for the sensor (2); a front actuation support rod (3) and the respective floating element (5); a rear actuation support rod (4) and the respective floating element (6). Due to the high reading precision of the level sensor according to the present invention, a liquid crystal display (LCD) is used in the vehicle dashboard, not only for monitoring the fuel level in the conventional manner, but all for tracking the fuel level during refuelling. In both cases, the information generated by the sensor is processed by the computer of the system proposed by the present invention.

Classes IPC  ?

• G01N 23/18 - Recherche de la présence de défauts ou de matériaux étrangers

Abrégé

The present invention relates to a method for growing autologous dendritic cells in vitro. The method includes treating cells isolated from peripheral blood of a mammal, with interleukines and cytokines, as well as tumour antigens taken from the same organism as the cells. The cells obtained by the method according to the present invention can be used for the therapy of various types of cancer and infectious-parasitic diseases.

Classes IPC  ?

• C12N 5/0784 - Cellules dendritiquesLeurs progéniteurs
• A61K 35/14 - SangSang artificiel
• A61P 35/00 - Agents anticancéreux
• A61P 33/00 - Agents antiparasitaires

Abrégé

A method is described for producing an intelligent label and solutions in ampoules, besides compositions based on conjugated polymers for monitoring radiation doses, the label and solutions, in an organic solvent, of (i) an electronic polymer (1-2000 μg/mL) and at least one organic crystal, inorganic crystal or luminescent dye (1-2000 μg/mL), or (ii) a combination of electronic polymers (1-2000 μg/mL), with solutions of said luminescent materials. The film-like label is obtained by drying solutions of luminescent materials on glass plates. The preferred materials are poly(2-methoxy,5-ethyl(2-hexyloxy)-p-phenylenevinylene) (MEH-PPV) as the preferred polymer and [aluminium-tris(8-hydroxyquinoline)] (Alq3) as the preferred organic crystal, besides various organic and inorganic dyes. The label and solutions in ampoules have a large variety of uses, as dosimetres of both ionising and non-ionising radiation, with therapeutic and technological aims, such as foodstuff irradiation in order to delay the ripening process.

Classes IPC  ?

• C08L 65/02 - Polyphénylènes
• C08L 53/02 - Compositions contenant des copolymères séquencés possédant au moins une séquence d'un polymère obtenu par des réactions ne faisant intervenir que des liaisons non saturées carbone-carboneCompositions contenant des dérivés de tels polymères contenant des monomères vinylaromatiques et des diènes conjugués
• G01T 1/00 - Mesure des rayons X, des rayons gamma, des radiations corpusculaires ou des radiations cosmiques
• G01J 1/00 - Photométrie, p. ex. posemètres photographiques
• A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations

Abrégé

The present invention relates to pharmaceutical compositions containing an isolated fraction of bee apitoxin, of low allergenicity, with analgesic and anti-inflammatory properties, for treating patients suffering from rheumatoid arthritis or other painful inflammatory conditions.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses

Abrégé

The present invention relates to a process fpr the thermal treatment of biomass and/or solid waste from municipal, industrial, agricultural or institutional sources, including health services, which contain carbonaceous material of biogenic or non-biogenic origin in their composition. The thermal process passes through multiple stages, using reactors with indirect heating by means of a heat transfer fluid, thus promoting the desorption and/or thermal decomposition of the material. The process can be applied to: torrefaction of wood or other types of biomass in order to obtain torrefied wood or biomass; pyrolysis or wood or other types of biomass in order to obtain charcoal; pyrolysis of waste from municipal, industrial, agricultural or institutional sources, including health services, without restriction as to the uses of the process; thermal desorption of substances present in soils, sands and/or waste contaminated with organic materials such as hydrocarbons from petroleum and derivatives thereof.

Classes IPC  ?

• C10B 57/02 - Procédés de carbonisation ou de cokéfaction à phases multiples
• C10B 53/02 - Distillation destructive spécialement conçue pour des matières premières solides particulières ou sous forme spéciale de matières contenant de la cellulose

Abrégé

The present invention concerns a method for male erectile function potentiating by means of toxin Tx2-6 from the spider Phoneutria nigriventer.

Classes IPC  ?

• C12N 15/12 - Gènes codant pour des protéines animales
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains

Abrégé

The present invention provides a method for quantifying the levels of allergen-specific human IgG antibody subclasses, particularly of IgG1, IgG2, IgG3 or IgG4 subclasses, using a reverse ELISA immunoenzymatic technique. The present invention also provides a kit comprising microtitration plates for ELISA already sensitized/covered with monoclonal antibodies, for example, anti-Der p 1 or anti-Der p 2, total extract from corresponding allergens, labeled secondary antibodies, enzymatic conjugate, enzymatic substrate and chromogenic buffer, as well as reference positive and negative control sera. The present invention provides high sensitivity for the detection of specific IgG antibody subclasses and is a potential tool for the control and attendance of allergen-specific immunotherapy in patients with allergic respiratory disease.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/536 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec formation d'un complexe immunologique en phase liquide

Abrégé

is a technological solution that mixes administrative, computational and electronic engineering knowledge, and aims to modernize the whole apicultural production chain. The administrative part of the ensemble proposes the use of small electronic equipment for all the activities of the field and industrial jobs. The equipment is carried attached to the user's body, in such a manner that its presence influences the minimum possible in the user's quotidian activities, maximizing its ergonomics quality. The equipment can be activated without using hands. Still from an administrative point of view, logistic processes for transferring and storing items, coupled with a complex but intuitive system of classes and subclasses of codes, assessed and monitored by the electronic equipment, register everything, in an automatic and inductive manner, leading the user to an inevitable recording of all the details in its daily activities. The computational and electronics knowledge used make possible that all the details idealized to register activities, the transfers and assets used, can be executed in practice. The result of the use of this solution is a conscious consumer, aware of the quality of the products consumed, a producer who is able to highlight the quality of his products produced with care, and a sector that learns how to know its potentials and can have modern and efficient tools to augment its productivity.

Classes IPC  ?

• G06F 1/16 - Détails ou dispositions de structure